Combined effect of fasting blood glucose and serum uric acid on nonalcoholic fatty liver disease

Table 3 NAFLD ORs (95% CIs) in relation to FBG and SUA in participants with self-reported T2DM

T2DM participants		No. of subjects	No. of Cases	Basic-adjusted OR (95%CI) ^a	Multi-adjusted OR (95%CI) ^b
Fasting				1.11 (1.05–1.18)	1.12 (1.04–1.20)
< 6		335	136	Reference	Reference
6–7		363	195	1.86 (1.37–2.53)	1.69 (1.17–2.43)
≥ 7		569	308	1.85 (1.40–2.44)	1.79 (1.28–2.51)
Uric Acid				1.24 (1.15–1.35)	1.17 (1.06–1.29)
Normal		984	470	Reference	Reference
Hyperuricemia		279	166	1.69 (1.28–2.22)	1.46 (1.06–2.02)
Fasting	Uric Acid
< 6	Normal	257	98	Reference	Reference
6–7	Normal	280	146	1.92 (1.35–2.73)	1.63 (1.07–2.49) ^*
≥ 7	Normal	447	226	1.78 (1.29–2.46)	1.66 (1.13–2.44) ^**
< 6	Hyperuricemia	78	38	1.60 (0.95–2.69)	1.20 (0.64–2.24)
6–7	Hyperuricemia	82	49	2.89 (1.72–4.87)	2.38 (1.29–4.40) ^*
≥ 7	Hyperuricemia	119	79	3.56 (2.23–5.68)	2.92 (1.68–5.05) ^**

^a Adjusted age and sex
^b Adjusted age, sex, education, smoking, drinking, physical exercise, body mass index, hypertension, and total cholesterol
^* Measures of additive interaction for nonalcoholic fatty liver disease:
Relative excess risk due to interaction: 0.487, 95%CI: -0.903-1.878, P > 0.05;
Attributable proportion: 0.220, 95%CI: -0.329-0.770, P > 0.05;
Synergy index: 1.672, 95%CI: 0.362–7.733, P > 0.05
^** Measures of additive interaction for nonalcoholic fatty liver disease:
Relative excess risk due to interaction: 1.034, 95%CI: -0.362-2.430, P > 0.05;
Attributable proportion: 0.369, 95%CI: -0.007-0.746, P > 0.05;
Synergy index: 2.350, 95%CI: 0.671–8.226, P > 0.05

ISSN: 1476-511X